SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-014091
Filing Date
2023-04-24
Accepted
2023-04-24 16:16:04
Documents
50
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q abio-20230331.htm   iXBRL 10-Q 1546159
2 EX-31.1 abio-ex31_1.htm EX-31 14371
3 EX-31.2 abio-ex31_2.htm EX-31 14197
4 EX-32.1 abio-ex32_1.htm EX-32 19346
  Complete submission text file 0000950170-23-014091.txt   4594396

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abio-20230331_pre.xml EX-101.PRE 182911
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abio-20230331_lab.xml EX-101.LAB 267261
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT abio-20230331_cal.xml EX-101.CAL 28058
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abio-20230331_def.xml EX-101.DEF 68668
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abio-20230331.xsd EX-101.SCH 26801
44 EXTRACTED XBRL INSTANCE DOCUMENT abio-20230331_htm.xml XML 617360
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 23840292
SIC: 2835 In Vitro & In Vivo Diagnostic Substances